• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

CNS Summit 2016 Abstracts of Poster Presentations
Conclusion: Subjects with acutely exacerbated schizophrenia who were eligible for discharge from the inpatient setting and who completed the study demonstrated high rates of adherence using the mobile AI application. Subjects were able to easily use the technology. Use of the platform did not appear to increase the dropout rate. This study demonstrates the feasibility of using AI platforms to ensure high adherence, provide reliable adherence data, and rapidly detect nonadherence in CNS trials. Disclosures/funding: Adam Hanina and Laura Shafner are employees of AiCure, New York, New York, and consultants to Takeda. Xinxin D...
Source: Innovations in Clinical Neuroscience - February 1, 2017 Category: Neuroscience Authors: ICN Online Editor Tags: Assessment Tools biomarkers Cognition Current Issue Devices Drug Development Evaluations Genetics Medical Issues Neurology Patient Assessment Proceedings Psychiatry Psychopharmacology Scales Supplements Technology Trial M Source Type: research

Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials
This article reviews CVOTs completed to date for the class of long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs; liraglutide, exenatide extended-release, albiglutide, dulaglutide, semaglutide injectable, semaglutide oral) and implications for clinical management of T2DM. All CVOTs have confirmed long-acting GLP-1RAs to be noninferior to (not worse than) placebo with regard to first occurrence of a primary outcome of three-point major adverse cardiovascular events (MACE; composite outcome of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke). Further, a number of the studies demonstrated a ...
Source: Journal of the American Academy of Physician Assistants - July 30, 2020 Category: Primary Care Tags: Long-Acting GLP-1 Receptor Agonists Source Type: research